At the beginning of January, the FDA announced that it was authorizing Florida’s Agency for Health Care Administration to import certain prescription drugs from Canada. Leslie Isenegger, practice leader, corporate pricing and public affairs at Real Chemistry, answers some key questions about the implications the program could have on the pharma industry.
Tag Archive for: patient access
While gene therapies for treating sickle cell disease are promising, they will only be cost effective in the U.S. if priced below $2 million, according to a new modeling analysis.
The pharma companies may be served with subpoenas to appear before the Senate health committee to explain why their products are much more expensive in the U.S. than in other countries, according to chairman Sen. Bernie Sanders.
As one integrated platform, Inizio Evoke now delivers a more advanced offering and more intuitive experience for its clients and people.
The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.
The U.S. Supreme Court, which in 2022 ended its recognition of a constitutional right to abortion, today agreed to hear a bid by President Joe Biden’s administration to preserve broad access to the abortion pill, setting up another major ruling on reproductive rights set to come in a presidential election year.
It is the biggest change to existing medical laws in two decades, aiming to ensure all Europeans have access to innovative treatments and drugs.
Part I: From patient access issues to significant cost cutting to the Inflation Reduction Act, there are a host of challenges that the industry is up against in 2024. Our experts weigh in.
Part V: Cost pressures, increasing value while improving health outcomes, and leveraging real-world evidence are top of mind.
With the biopharma industry’s looming wave of gene therapy submissions and potential approvals, the senior senator is laying the groundwork for a legislative initiative to improve access to these expensive treatments.
